ARS Pharmaceuticals advertising spend, FY2025

ARS Pharmaceuticals (SPRY) reported $99.8M of advertising expense for the fiscal year ended Dec 31, 2025. That is 118.4% of revenue of $84.3M. Up 698.4% from FY2024. Formerly Silverback Therapeutics.

Ad spend, FY2025
$99.8M
year ended Dec 31, 2025
Change vs prior year
+698.4%
vs FY2024
Share of revenue
118.4%
of $84.3M revenue
Rank by ad spend
#344
of 458 companies

Key facts

  • Ad spend is 8.0x its FY2024 level ($12.5M), faster than revenue (0.9x).
  • ARS Pharmaceuticals spends more on advertising than 25% of the 458 US-listed companies tracked. Its ad-to-revenue ratio is 26x the median of 4.5%.

Ad spend by fiscal year

$0 $25M $50M $75M $100M FY2024 (ended 2024-12-31): $12.5M 2024 FY2025 (ended 2025-12-31): $99.8M 2025 $99.8M

Ad spend as % of revenue

0% 50% 100% 150% FY2024 (ended 2024-12-31): 14.0% 2024 FY2025 (ended 2025-12-31): 118.4% 2025 118.4%

Ad spend in context, FY2025

Advertising was 43.4% of selling, general and administrative expense. Advertising was 7.6x research and development spending. The company reported an operating loss of $179M.

Advertising $99.8M AdvertisingExpense
Selling, general and administrative $230M ad spend = 43.4%
Research and development $13.2M ad spend = 7.6x R&D
Operating loss -$179M
Net loss -$171M

Same fiscal year and filing as the ad spend. Selling and marketing and SG&A usually include advertising.

History

Download CSV
Fiscal year Period end Ad spend YoY Revenue Ad / revenue Tag Filing
FY2025 Dec 31, 2025 $99.8M +698.4% $84.3M 118.4% AdvertisingExpense 10-K Mar 9, 2026
FY2024 Dec 31, 2024 $12.5M n/a $89.1M 14.0% AdvertisingExpense 10-K Mar 9, 2026

Ad spend, revenue and the ratio come from the linked filing. YoY compares each year with the fiscal year directly before it, under the same tag. A gap, a change of tag or a change of fiscal year end leaves it blank.

What the figure is

Advertising costs as disclosed in the annual report (XBRL tag AdvertisingExpense).

Compared with similar spenders

The 6 companies closest to ARS Pharmaceuticals in latest-year ad spend.

Rank Company Ad spend Ad / revenue YoY Fiscal year
338 AutoZone $101M 0.5% -7.6% FY2026
339 Sonic Automotive $101M 0.7% +19.8% FY2025
340 A. O. Smith $101M 2.6% +0.8% FY2025
341 Alaska Air Group $101M 0.7% +4.1% FY2025
342 Wise Group $101M 4.0% +60.8% FY2026
343 Ethos Technologies $100M 25.8% +57.8% FY2025
344 ARS Pharmaceuticals $99.8M 118.4% +698.4% FY2025

Full ranking of 458 companies · Biggest increases #1 · Highest ad-to-revenue #1 · New $50M spenders #4 · More on ads than R&D #22 · Ads above operating profit #120

Questions

How much does ARS Pharmaceuticals spend on advertising?

ARS Pharmaceuticals spent $99.8M on advertising in fiscal 2025, the year ended Dec 31, 2025, according to its 10-K filed Mar 9, 2026.

What percentage of revenue does ARS Pharmaceuticals spend on advertising?

118.4% of revenue in fiscal 2025 ($99.8M against $84.3M). The median across the 458 companies tracked is 4.5%.

Is ARS Pharmaceuticals spending more on advertising?

Yes. Ad spend rose 698.4% in fiscal 2025 from fiscal 2024.

How does ARS Pharmaceuticals rank by advertising spend?

#344 of 458 US-listed companies with $50M or more in ad spend, ranked on each company's latest fiscal year.

Does ARS Pharmaceuticals spend more on advertising than on R&D?

Yes. In fiscal 2025 it spent $99.8M on advertising and $13.2M on research and development.

What does ARS Pharmaceuticals's advertising figure include?

Advertising costs as disclosed in the annual report (XBRL tag AdvertisingExpense).

Company and source

Filing
10-K for FY2025, filed Mar 9, 2026
Accession number
0001193125-26-097478
Company
ARS Pharmaceuticals, Inc., CIK 1671858, SIC 2834 (Pharmaceutical Preparations)
Former names
Silverback Therapeutics
Headquarters
San Diego, CA
Incorporated in
DE
Fiscal year ends
December 31
Listed on
Nasdaq
SEC filer status
Non-accelerated filer, Smaller reporting company
Data
SEC EDGAR XBRL company facts, retrieved Nov 17, 2026. Methodology.
Cite
ARS Pharmaceuticals advertising spend, FY2024-FY2025. Aleksei Trudov, io.trudov.com, from SEC EDGAR XBRL company facts (latest: 10-K filed Mar 9, 2026), retrieved Nov 17, 2026. https://io.trudov.com/company/ars-pharmaceuticals/advertising-spend/
Download
CSV, all years · CSV, all 458 companies